Theorem Clinical Research Names Joseph Sgherza to Head Infectious Disease Franchise

Theorem Clinical Research Names Joseph Sgherza to Head Infectious Disease Franchise

(King of Prussia, PA; Sept. 26, 2013) — A veteran of 24 years in the pharmaceutical, biotech and CRO industries, Joseph Sgherza has been named vice president of biopharmaceutical development for the infectious disease franchise of Theorem Clinical Research.

"Joe is truly a leader in this area," said Theorem President and CEO John Potthoff. "He has developed and managed numerous global clinical programs in infectious diseases in all phases, from launch to patent expiration, and led clinical development teams to eight successful NDAs in infectious disease, hepatology and oncology."

Prior to joining Theorem, Sgherza was portfolio director for PAREXEL International Corporation, where he was responsible for the operational execution of pharmaceutical trials in infectious disease, biologics and oncology. As executive vice president for SPRI Clinical Trials, Sgherza successfully hired, trained and developed 78 team members in Ukraine and other areas in Eastern Europe for a new clinical research operations division, while simultaneously conducting 15 clinical trial programs there over three years. He also held posts as head of clinical operations for Neeman Medical International, as site management operations director for Duke Clinical Research and as senior manager of the worldwide anti-infective medical team for Pfizer.

"We are building our therapeutic franchises with the best people we can find in each field," Potthoff said. "Joe Sgherza is a perfect fit for Theorem."


About Theorem Clinical Research
Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's top pharmaceutical, biotech and medical device companies. As a forerunner in medical device and drug-device combination trials with notable capabilities in pharmaceuticals and biologics, Theorem offers deep expertise in a broad range of therapeutic areas and in all phases of development. With some of the industry's top scientists and most advanced clinical analytics capabilities, Theorem ensures smooth-running, successful trials. For the full-service, right-size global research partner, don't think twice. THINK THEOREM.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.